KR20160035600A - 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 - Google Patents

고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 Download PDF

Info

Publication number
KR20160035600A
KR20160035600A KR1020167004778A KR20167004778A KR20160035600A KR 20160035600 A KR20160035600 A KR 20160035600A KR 1020167004778 A KR1020167004778 A KR 1020167004778A KR 20167004778 A KR20167004778 A KR 20167004778A KR 20160035600 A KR20160035600 A KR 20160035600A
Authority
KR
South Korea
Prior art keywords
conjugate
seq
antibody
cancer
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167004778A
Other languages
English (en)
Korean (ko)
Inventor
실비 아싸두리앙
도미니끄 미냐르
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20160035600A publication Critical patent/KR20160035600A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A61K47/48407—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K47/48569—
    • A61K47/48584—
    • A61K47/48638—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167004778A 2013-08-02 2014-07-30 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 Withdrawn KR20160035600A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306119 2013-08-02
EP13306119.2 2013-08-02
PCT/EP2014/066345 WO2015014879A1 (en) 2013-08-02 2014-07-30 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
KR20160035600A true KR20160035600A (ko) 2016-03-31

Family

ID=49036539

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167004778A Withdrawn KR20160035600A (ko) 2013-08-02 2014-07-30 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도

Country Status (12)

Country Link
US (1) US20160347856A1 (cg-RX-API-DMAC7.html)
EP (1) EP3027218A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016525560A (cg-RX-API-DMAC7.html)
KR (1) KR20160035600A (cg-RX-API-DMAC7.html)
CN (1) CN105592861A (cg-RX-API-DMAC7.html)
AU (1) AU2014298514A1 (cg-RX-API-DMAC7.html)
CA (1) CA2919932A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690321A1 (cg-RX-API-DMAC7.html)
IL (1) IL243843A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016001541A (cg-RX-API-DMAC7.html)
TW (1) TW201605479A (cg-RX-API-DMAC7.html)
WO (1) WO2015014879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
GB201506388D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CN112105384B (zh) * 2017-01-18 2024-08-23 苏州启航纳米药物有限公司 癌糖肽的单克隆和人源化抗体
EP3665161B1 (en) * 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
BR112021008526A2 (pt) * 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752950B2 (en) * 1998-02-25 2002-10-03 Wakamoto Pharmaceutical Co., Ltd. Remedies for corneal epithelium disturbance
CN103554261B (zh) * 2003-07-21 2017-03-01 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
MX2008002607A (es) * 2005-08-22 2008-03-19 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
KR20120080611A (ko) * 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커

Also Published As

Publication number Publication date
IL243843A0 (en) 2016-04-21
EP3027218A1 (en) 2016-06-08
CA2919932A1 (en) 2015-02-05
WO2015014879A1 (en) 2015-02-05
AU2014298514A1 (en) 2016-03-10
JP2016525560A (ja) 2016-08-25
TW201605479A (zh) 2016-02-16
WO2015014879A9 (en) 2015-11-19
MX2016001541A (es) 2016-08-18
CN105592861A (zh) 2016-05-18
EA201690321A1 (ru) 2016-12-30
US20160347856A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
KR102795812B1 (ko) 항-메소텔린 항체 및 이의 항체 약물 콘쥬게이트
KR20160035600A (ko) 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도
US20230087871A1 (en) Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CN115484989A (zh) 含有抗ceacam5抗体缀合物、曲氟尿苷和三氟尿嘧啶的抗肿瘤组合
KR20230005176A (ko) 항-ceacam5 항체 콘쥬게이트 및 세툭시맙을 함유하는 항종양 조합물
CN115427082A (zh) 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
WO2017194568A1 (en) Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
RU2835019C1 (ru) Противоопухолевые комбинации, включающие конъюгаты на основе антитела к ceacam5, трифлуридин и типирацил
HK40030271A (en) Anti-mesothelin antibody and antibody-drug conjugate thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid